HC Wainwright Issues Positive Outlook for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Investment analysts at HC Wainwright raised their Q4 2025 earnings estimates for Corcept Therapeutics in a research report issued on Thursday, February 27th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will earn $0.73 per share for the quarter, up from their prior forecast of $0.70. HC Wainwright currently has a “Buy” rating and a $115.00 target price on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ FY2029 earnings at $8.52 EPS.

Other equities research analysts have also recently issued research reports about the stock. StockNews.com cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. Piper Sandler raised their target price on shares of Corcept Therapeutics from $67.00 to $78.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Canaccord Genuity Group raised their target price on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $99.75.

Corcept Therapeutics Trading Up 1.2 %

NASDAQ:CORT opened at $60.58 on Friday. The company’s 50 day moving average price is $59.96 and its 200-day moving average price is $51.40. Corcept Therapeutics has a 52 week low of $20.84 and a 52 week high of $75.00. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The stock has a market cap of $6.35 billion, a price-to-earnings ratio of 48.08 and a beta of 0.58.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.11). Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The firm had revenue of $181.89 million for the quarter, compared to analysts’ expectations of $200.12 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of CORT. Capital Performance Advisors LLP bought a new stake in shares of Corcept Therapeutics during the 3rd quarter valued at $25,000. Kestra Investment Management LLC bought a new stake in shares of Corcept Therapeutics during the 4th quarter valued at $27,000. Canada Pension Plan Investment Board bought a new stake in shares of Corcept Therapeutics during the 4th quarter valued at $40,000. National Bank of Canada FI bought a new stake in shares of Corcept Therapeutics during the 4th quarter valued at $42,000. Finally, USA Financial Formulas bought a new stake in shares of Corcept Therapeutics during the 4th quarter valued at $54,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Insider Transactions at Corcept Therapeutics

In other news, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $59.46, for a total transaction of $130,812.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Sean Maduck sold 20,000 shares of Corcept Therapeutics stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the transaction, the insider now owns 85,318 shares in the company, valued at $4,299,174.02. This represents a 18.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,600 shares of company stock worth $1,399,576 in the last 90 days. 20.50% of the stock is currently owned by insiders.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.